JPWO2020132190A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132190A5 JPWO2020132190A5 JP2021536072A JP2021536072A JPWO2020132190A5 JP WO2020132190 A5 JPWO2020132190 A5 JP WO2020132190A5 JP 2021536072 A JP2021536072 A JP 2021536072A JP 2021536072 A JP2021536072 A JP 2021536072A JP WO2020132190 A5 JPWO2020132190 A5 JP WO2020132190A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cdr2
- cdr3
- cdr1
- muc18
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims 6
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims 6
- 101100458666 Homo sapiens MCAM gene Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 239000013598 vector Substances 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000006306 Antigen Receptors Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 108010032795 CD8 receptor Proteins 0.000 claims 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims 1
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 claims 1
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 claims 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- -1 ICOS Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 102100022339 Integrin alpha-L Human genes 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108700010039 chimeric receptor Proteins 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122567 | 2018-12-21 | ||
| CNPCT/CN2018/122567 | 2018-12-21 | ||
| PCT/US2019/067387 WO2020132190A1 (en) | 2018-12-21 | 2019-12-19 | Antibodies specific to muc18 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022514693A JP2022514693A (ja) | 2022-02-14 |
| JPWO2020132190A5 true JPWO2020132190A5 (https=) | 2022-12-16 |
| JP2022514693A5 JP2022514693A5 (https=) | 2022-12-16 |
| JP7575102B2 JP7575102B2 (ja) | 2024-10-29 |
Family
ID=71101893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536072A Active JP7575102B2 (ja) | 2018-12-21 | 2019-12-19 | Ｍｕｃ１８に特異的な抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12371509B2 (https=) |
| EP (1) | EP3898698B1 (https=) |
| JP (1) | JP7575102B2 (https=) |
| CN (2) | CN113423736B (https=) |
| AU (1) | AU2019401647A1 (https=) |
| TW (1) | TWI851634B (https=) |
| WO (1) | WO2020132190A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117343187A (zh) | 2018-12-21 | 2024-01-05 | 普众发现医药科技(上海)有限公司 | 对muc18特异性的抗体 |
| EP4221726A4 (en) * | 2020-09-30 | 2024-10-30 | Baylor College of Medicine | CYTOTOXIC AND CO-STIMULATORY CHIMERIC ANTIGEN RECEPTORS |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| JP2025535447A (ja) * | 2022-10-19 | 2025-10-24 | マルチチュード・セラピューティックス・インコーポレーテッド | 抗体－薬物コンジュゲート、その調製方法および使用 |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| KR20260016952A (ko) | 2023-05-23 | 2026-02-04 | 사나 바이오테크놀로지, 인크. | 탠덤 퓨소젠 및 관련 지질 입자 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN120463814A (zh) * | 2024-02-07 | 2025-08-12 | 北京艺妙神州医药科技有限公司 | 靶向muc18的嵌合抗原受体及其用途 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ES2116269T3 (es) | 1989-03-21 | 1998-07-16 | Vical Inc | Expresion de secuencias exogenas de polinucleotidos en un vertebrado. |
| JP4041535B2 (ja) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JP3534749B2 (ja) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | アデノウイルスが介在する胃腸管への遺伝子の輸送 |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| ES2328424T3 (es) | 1993-09-15 | 2009-11-12 | Novartis Vaccines And Diagnostics, Inc. | Vectores de alfavirus recombinantes. |
| EP1637608B1 (en) | 1993-10-25 | 2009-07-22 | CANJI, Inc. | Recombinant adenoviral vector and methods of use |
| PT729351E (pt) | 1993-11-16 | 2000-12-29 | Skyepharma Inc | Vesiculas com libertacao controlada de activos |
| WO1995030763A2 (en) | 1994-05-09 | 1995-11-16 | Chiron Viagene, Inc. | Retroviral vectors having a reduced recombination rate |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| WO1997042338A1 (en) | 1996-05-06 | 1997-11-13 | Chiron Corporation | Crossless retroviral vectors |
| US6824995B1 (en) * | 1998-03-03 | 2004-11-30 | Emory University | Diagnostic for metastatic prostate cancer |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1158997A2 (en) | 1999-03-09 | 2001-12-05 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CA2471849A1 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| EP1467756A4 (en) | 2001-12-28 | 2007-03-21 | Abgenix Inc | METHODS OF USING ANTI-MUC18 ANTIBODIES |
| KR101672271B1 (ko) | 2007-12-18 | 2016-11-03 | 바이오얼라이언스 씨.브이. | 암세포에서 발현된 ｃｄ-43 및 ｃｅａ 상의 탄수화물 함유 에피토프를 인식하는 항체 및 그것의 사용 방법 |
| CN101245101B (zh) * | 2008-01-31 | 2013-10-16 | 中国科学院生物物理研究所 | 抗人cd146的单克隆抗体，包含其的组合物，检测可溶性cd146的方法 |
| EP2430051B1 (en) * | 2009-05-14 | 2016-03-23 | Institut National de la Santé et de la Recherche Medicale | Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2013143026A1 (en) | 2012-03-31 | 2013-10-03 | Abmart (Shanghai) Co., Ltd | Peptide and antibody libraries and uses thereof |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| WO2015044218A1 (en) * | 2013-09-24 | 2015-04-02 | Oncoinvent As | Monoclonal antibody and derivatives |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| CN104650231A (zh) | 2015-02-13 | 2015-05-27 | 南京任诺药业有限公司 | 一种具备高效中和活性的人源化抗人cd146单克隆抗体 |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| US20190192573A1 (en) * | 2016-08-19 | 2019-06-27 | Oncoinvent As | Anti-osteosarcoma car-t derived from the antibody oi-3 |
| WO2018220467A1 (en) * | 2017-05-30 | 2018-12-06 | Foroogh Nejatollahi | Anti-muc18 human immunotoxin and applications thereof |
| CN108129567B (zh) * | 2018-01-09 | 2019-02-26 | 南京任诺药业有限公司 | 一种具备高效中和活性的人源化抗人cd146单克隆抗体 |
| CN117343187A (zh) | 2018-12-21 | 2024-01-05 | 普众发现医药科技(上海)有限公司 | 对muc18特异性的抗体 |
-
2019
- 2019-12-19 WO PCT/US2019/067387 patent/WO2020132190A1/en not_active Ceased
- 2019-12-19 TW TW108146801A patent/TWI851634B/zh active
- 2019-12-19 CN CN201980092134.1A patent/CN113423736B/zh active Active
- 2019-12-19 JP JP2021536072A patent/JP7575102B2/ja active Active
- 2019-12-19 EP EP19899845.2A patent/EP3898698B1/en active Active
- 2019-12-19 CN CN202310816116.1A patent/CN117447599A/zh active Pending
- 2019-12-19 AU AU2019401647A patent/AU2019401647A1/en active Pending
-
2021
- 2021-06-17 US US17/350,995 patent/US12371509B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| JPWO2020132190A5 (https=) | ||
| CN112574307A (zh) | 抗人Claudin18.2抗体及其应用 | |
| JP2020508655A5 (https=) | ||
| JP2019517773A (ja) | 抗ｌａｇ−３抗体 | |
| JPWO2019129221A5 (https=) | ||
| JP2018532383A5 (https=) | ||
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| KR20170102167A (ko) | 항-pd-l1 항체 | |
| JP2018526981A5 (https=) | ||
| JP2021531825A5 (https=) | ||
| JP2024001073A5 (https=) | ||
| AU2022332499A1 (en) | Fap/cd40 binding molecule and medicinal use thereof | |
| IL316226A (en) | Anti-ror1 antibody and ror1-targeting engineered cells | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| JP2021523949A5 (https=) | ||
| JPWO2022256563A5 (https=) | ||
| JPWO2020011973A5 (https=) | ||
| JPWO2020159754A5 (https=) | ||
| JPWO2019245991A5 (https=) | ||
| JPWO2020016661A5 (https=) | ||
| CN117700558B (zh) | 一种单克隆抗gprc5d抗体和抗gprc5d-car-nk细胞 | |
| JP7641292B2 (ja) | 抗ｃｄ１９抗体、その使用方法及び製造方法 | |
| JPWO2019219064A5 (https=) | ||
| JP2020533953A5 (https=) |